Stockscreener 앱 받기
5.25
0.19%
-0.010
시간 외 거래:
5.15
-0.10
-1.90%
전일 마감가:
$5.26
열려 있는:
$5.26
하루 거래량:
1.03M
Relative Volume:
0.98
시가총액:
$314.45M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-7.00
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
+3.35%
1개월 성능:
+12.90%
6개월 성능:
-11.54%
1년 성능:
+2.94%
1일 변동 폭
$5.04
$5.37
1주일 범위
$4.99
$5.37
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.25 | 315.05M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra price target raised to $9 from $6 at Jones Trading on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th A - GuruFocus
Aldeyra CEO to Share Exclusive Ophthalmology Pipeline Updates at H.C. Wainwright Conference - Stock Titan
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionTremendous portfolio expansion - Jammu Links News
Is Aldeyra Therapeutics Inc. a good long term investmentBuild a portfolio that outperforms the market - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock price move sharplyFree Trend-Following Techniques - Jammu Links News
How does Aldeyra Therapeutics Inc. generate profit in a changing economyPowerful profit generation - Jammu Links News
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Strongest growth potential - Jammu Links News
When is Aldeyra Therapeutics Inc. stock expected to show significant growthSky-high profits - Jammu Links News
Published on: 2025-08-02 20:17:22 - beatles.ru
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - Jammu Links News
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - Jammu Links News
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”AI Powered Entry Points That Work - Jammu Links News
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Why did ALDX's EPS remain stagnant in recent quarters? - AInvest
How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketUnmatched market performance - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - Jammu Links News
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - printweek.in
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com
Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
3.70%
자본화:
|
볼륨(24시간):